The tracer in question is [¹⁸F] AlF-NOTA-Pentixafor, often abbreviated simply as [¹⁸F] Pentixafor. Unlike FDG, which reports on glucose consumption, Pentixafor homes in on CXCR4, a chemokine receptor that acts as a homing beacon for many cancers of the immune system. CXCR4 is overexpressed on the surface of numerous B-cell malignancies, and it plays a genuine biological role in the disease, guiding malignant cells to particular tissue niches and contributing to their survival and dissemination. A tracer that binds CXCR4 therefore does not merely detect a metabolic side effect of cancer; it detects a molecule the cancer actively deploys. This mechanistic distinction is what makes the new study scientifically interesting, because it asks whether a biologically targeted signal can outperform a metabolic one in a tumor type where metabolism is unreliable.

The study was deliberately framed as exploratory. Twenty patients, eleven men and nine women, all with pathologically confirmed gastric MALT lymphoma, underwent both [¹⁸F] FDG PET/CT and [¹⁸F] Pentixafor PET/CT scans. Scanning each patient with both tracers is the strongest design feature of the work, because it allows head-to-head comparison within the same individuals, eliminating the confounding that arises when different cohorts are compared across studies. The researchers then compared how often each tracer detected gastric lesions, and they measured semiquantitative parameters including SUVmax, SUVmean, and the tumor-to-blood pool ratio, or TBR, for both gastric lesions and any disease that had spread beyond the stomach. A statistical test known as the McNemar test, which is specifically designed for paired comparisons of detection rates in the same subjects, was used to assess whether the difference between the two tracers reached significance.

The headline result was numerically striking even if statistically cautious. [¹⁸F] Pentixafor PET/CT was positive in nine of the twenty gastric lesions, a detection rate of forty-five percent, whereas [¹⁸F] FDG PET/CT flagged only four of twenty, or twenty percent. In other words, the CXCR4-targeted tracer found more than twice as many gastric lesions as the standard metabolic tracer. The median SUVmax among Pentixafor-positive gastric lesions was 4.2, with a range running from 1.1 to 7.2, indicating that uptake intensity varied considerably from patient to patient. Yet when the authors subjected this apparent superiority to formal statistical testing, the difference did not reach significance, a finding the team attributes candidly to the small sample size and the non-matched nature of some of the semiquantitative comparisons. This is a crucial nuance: the study does not prove Pentixafor is better, but it provides the kind of preliminary signal that justifies larger, definitive trials.

Perhaps the most intriguing findings came from the subset of patients whose disease had escaped the stomach. Among the five patients with extragastric disease, [¹⁸F] Pentixafor uptake was numerically higher in the lesions outside the stomach than in the gastric lesions themselves, whereas FDG showed no consistent pattern at all. When the researchers pooled lymph-node and pulmonary lesions, the same trend emerged: these sites took up Pentixafor more avidly than FDG. This observation carries real clinical weight, because the management of gastric MALT lymphoma depends heavily on accurate staging. A patient whose disease appears confined to the stomach may be treated with local approaches such as antibiotics targeting Helicobacter pylori infection or radiotherapy, whereas disseminated disease demands systemic therapy. A tracer that reliably illuminates disease beyond the stomach could therefore change treatment decisions in ways that a marginal improvement in gastric detection alone could not.

The researchers also probed which clinical factors predicted a positive Pentixafor scan. The answer was unexpected and, in some respects, sobering. CT-visible gastric wall abnormality was significantly associated with positive Pentixafor PET/CT findings, with a P value below 0.001, making it the only variable that showed a clear statistical relationship. Age, sex, Lugano classification, and the Ki-67 proliferation index, all factors one might reasonably expect to correlate with tracer uptake, showed no significant associations. The association with CT wall abnormalities cuts both ways. On one hand, it suggests that Pentixafor uptake reflects genuine structural disease rather than noise. On the other hand, as the authors themselves note, it implies that the added benefit of the PET signal over CT alone may be limited: if the CT component already shows the abnormality, the radioactive tracer may be confirming rather than discovering it.

The authors are appropriately careful about the limits of their semiquantitative data. All SUV and TBR values are presented as descriptive statistics, and direct comparisons between the two tracers were not performed because the sample was small and the lesion sets were not fully matched. This restraint matters in a field where tracer enthusiasm can sometimes outrun evidence. Pentixafor has generated considerable excitement in nuclear medicine, with studies exploring its use in multiple myeloma, Waldenström macroglobulinemia, and various lymphomas, but each new tumor type demands its own rigorous evaluation. Gastric MALT lymphoma poses particular challenges for any PET tracer: the lesions are often shallow, diffuse, and low in tracer avidity, and physiological uptake in the stomach wall can obscure genuine pathology. A forty-five percent detection rate, while better than twenty percent, still leaves the majority of gastric lesions invisible to the targeted tracer.

Technically, the study also showcases an elegant radiochemistry approach. [¹⁸F] AlF-NOTA-Pentixafor is produced using the aluminum-fluoride labeling method, in which the fluorine-18 radionuclide is chelated to an aluminum ion that binds to the NOTA chelator conjugated to the Pentixafor peptide. This approach avoids the harsh conditions required for direct fluorination of peptides and allows the tracer to be synthesized from the same cyclotron-produced fluorine-18 that already powers FDG production in hospital radiopharmacies. That practical compatibility is not trivial. A tracer that requires exotic isotopes or complex on-site synthesis faces enormous barriers to clinical adoption, whereas one that can be manufactured with existing infrastructure has a realistic path into routine practice. The choice of fluorine-18 also gives the tracer a half-life of about 110 minutes, long enough for distribution and imaging but short enough to limit patient radiation dose.

What should clinicians and patients take away from this work? The honest answer is that it is a promising first step, not a practice-changing result. The study was conducted in accordance with the Declaration of Helsinki, approved by the Ethics Committee of Sichuan Cancer Hospital, and supported by institutional and national nuclear technology research funding, and the authors declare no competing interests. Its conclusions are explicitly framed as preliminary: Pentixafor detected more gastric lesions than FDG, the difference was not statistically significant, and the association with CT wall abnormalities suggests the tracer’s incremental value over conventional imaging remains to be demonstrated. The research team, led by co-first authors Shirong Chen and Xinyang Li and co-corresponding authors Zhuzhong Cheng and Ying Kou, calls for larger studies to define the clinical role of [¹⁸F] Pentixafor PET/CT in this disease.

Still, the broader scientific story is compelling. The study embodies a shift in nuclear medicine from imaging what cancer does, namely consuming glucose, toward imaging what cancer is, namely a cell bearing specific molecular markers. CXCR4 is one of the most heavily studied receptors in tumor biology, and the ability to visualize it noninvasively opens a window on disease biology that metabolic imaging cannot provide. For gastric MALT lymphoma, a cancer that has long evaded reliable molecular imaging, the preliminary numbers from Chengdu suggest that the CXCR4-targeted approach deserves a larger stage. If future studies with adequate statistical power confirm the trends seen here, particularly the apparent advantage in extragastric and nodal disease, then [¹⁸F] Pentixafor could become a genuine complement to FDG in the staging and surveillance of indolent lymphomas, turning a molecular homing receptor into a diagnostic beacon.

Subject of Research: Comparison of FDG and CXCR4-targeted Pentixafor PET/CT tracers for imaging gastric MALT lymphoma

Article Title: A preliminary evaluation of [¹⁸F] FDG and [¹⁸F] AlF-NOTA-Pentixafor PET/CT in gastric MALT lymphoma

Article References: Chen, S., Li, X., Cheng, Z., & Kou, Y. (2026). A preliminary evaluation of [¹⁸F] FDG and [¹⁸F] AlF-NOTA-Pentixafor PET/CT in gastric MALT lymphoma. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02816-z

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02816-z

Keywords: gastric MALT lymphoma, PET/CT, [¹⁸F] FDG, [¹⁸F] Pentixafor, CXCR4, molecular imaging, SUVmax, tumor-to-blood pool ratio, non-Hodgkin lymphoma, staging, radiopharmaceuticals, BMC Medical Imaging